LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

(2011) Giovanni Musso et al.   ANNALS OF MEDICINE

Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides

(2011) Robert E. Steinert et al.   BRITISH JOURNAL OF NUTRITION

The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY)

(2011) R.E. Steinert et al.   CLINICAL NUTRITION

Biology of Human Sodium Glucose Transporters

(2011) Ernest M. Wright et al.   PHYSIOLOGICAL REVIEWS

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database

(2010) E. S. Horton et al.   DIABETES CARE

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Carboxyl group-terminated polyamidoamine dendrimers bearing glucosides inhibit intestinal hexose transporter-mediated d-glucose uptake

(2010) Shinji Sakuma et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

SGLT2 inhibition — a novel strategy for diabetes treatment

(2010) Edward C. Chao et al.   NATURE REVIEWS DRUG DISCOVERY

Mechanisms of Glucose Homeostasis After Roux-en-Y Gastric Bypass Surgery in the Obese, Insulin-Resistant Zucker Rat

(2009) Katia Meirelles et al.   ANNALS OF SURGERY

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

(2009) J. P.H. Wilding et al.   DIABETES CARE

Projecting the Future Diabetes Population Size and Related Costs for the U.S.

(2009) E. S. Huang et al.   DIABETES CARE

Defining and Characterizing the Progression of Type 2 Diabetes

(2009) V. A. Fonseca   DIABETES CARE

Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-Ay mice

(2009) Kenji Katsuno et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

(2009) William N Washburn   EXPERT OPINION ON THERAPEUTIC PATENTS

Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery

(2009) D E Cummings   INTERNATIONAL JOURNAL OF OBESITY

Novell-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes

(2009) Nicole C. Goodwin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy and safety of incretin-based therapies: Clinical trial data

(2009) John White   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

(2009) Kausik K Ray et al.   LANCET

Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents

(2008) June Zhou et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(2008) S. Han et al.   DIABETES

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE

Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

(2008) Y. Fujimori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Polymer–phloridzin conjugates as an anti-diabetic drug that Inhibits glucose absorption through the Na+/glucose cotransporter (SGLT1) in the small intestine

(2007) Yusuke Ikumi et al.   JOURNAL OF CONTROLLED RELEASE